Trial · NCT05312671
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
NCT05312671, Phase 2, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer. Trials, record NCT05312671. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05312671
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
- NCT number
- NCT05312671
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 63 participants, estimated
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Conditions
- Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder
- Interventions
- Atezolizumab, Carboplatin, Cisplatin, Etoposide, Cystectomy
- First posted
- 2022-04-05
- Last updated
- 2026-06-25
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathologic complete response (ypCR) at cystectomy | up to 18 months | The number of participants with pathological complete responses (ypCR) at cystectomy. Pathologic complete response is defined as post-treatment cystectomy tumor stages N0 and M0, with T-stage T0. |
| Secondary | Number of participants with non-muscle invasive disease | up to 18 months | Non-muscle invasive disease is defined as \<ypT1N0 at cystectomy. |
| Secondary | Safety and tolerability of combination chemotherapy and cystectomy as assessed by number of participants experiencing adverse events | 4.5 years | Number of participants experiencing dose limiting toxicities and treatment-related adverse events, as defined by Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0). |
| Secondary | Incidence of brain metastases in follow-up | up to 5 years | Number of participants who develop brain metastases during follow-up |
| Secondary | 1-year overall survival rate (1-yr OS) | up to 4 years | Number of participants alive 1 year after last dose |
| Secondary | 2-year overall survival rate (2-yr OS) | up to 5 years | Number of participants alive 2 years after last dose |
| Secondary | Disease Free Survival | up to 5 years | Number of participants without disease recurrence |
| Secondary | Feasibility of atezolizumab administration with platinum and etoposide chemotherapy prior to surgery | up to 18 months | Number of participants during the first stage of the study (first 15 patients) proceeding to surgery without extended treatment related delays. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05312671
GET https://conductscience.org/api/trials/v1/NCT05312671/registered